Mini Symposia

Mini-symposia offer in-depth knowledge into a specific area of delivery science and technology, featuring multiple invited speakers sharing their research on the topic.

Monday, July 14 • 10:30 - 12:00

Interspecies Clinical Pharmacology Dosing Concepts

Invited Speakers

Robert Hunter, Parnell, US.A.
Mark Papich, North Carolina State University, U.S.A.
Steven Sutton, University of New England, U.S.A.

This symposium examines why dosing concepts in different species have to be carefully evaluated with few assumptions, except that they are unlikely to correlate very well. It is of particular relevance to preclinical researchers using animal models to study delivery systems as the basis for human PK/PD studies. The speakers will discuss cross-species physiological comparisons for drug delivery by several routes ranging from oral to topical, and will confirm why interspecies dosing on a mg/kg basis is rarely valid for PK studies.


Monday, July 14 • 15:00 - 16:30

Advancements to Develop and Deliver Biologics

Thank You Sponsor!
Invited Speakers

Stephen Buckley, Novo Nordisk A/S, Denmark
Kang Choon Lee, SungKyunKwan University, Korea
Rosie McLaughlin, Catalent Pharma Solutions, United Kingdom

Biologic drugs represent a significant share of the global pharmaceutical market. However, advances in controlled delivery methods that enhance activity, extend half-life, overcome biological barriers, and/or allow more convenient dosing are needed for the full benefit of biologics to be realized. The parenteral route has been the first choice in order to get to the market in a short time frame, but the possibility of efficient delivery via other routes of administration, including oral, pulmonary, and nasal is tantalizing. This mini-symposium will bring together experts from industry and academia to discuss the development and delivery of biologics and biosimilars.


Tuesday, July 15 • 10:30 - 12:00

Micro- and Nano-Encapsulation: From Innovation to Commercialization

Invited Speakers

Nathan Dormer, Orbis Biosciences, U.S.A.
Tom Tice, Evonik, U.S.A.
Ron Versic, Ronald T. Dodge Company, U.S.A.

Scale-up, regulatory and safety concerns, and economics are key considerations for transfer of micro- and nano-encapsulation techniques into commercial processes and products. This mini-symposium will give insight into today’s industrial chemical and physical encapsulation technologies with emphasis on practical and physical limits, scale-up challenges, and costs. Subject technologies include established processes as well as novel innovative processes such as inkjet printing, 3D printing, microfluidics, electro-spinning, and membrane techniques. These basic translational topics will be of interest for all industrial segments as novel technologies transition from a bench scale to production scale.


Tuesday, July 15 • 13:30 - 15:00

Cancer Epigenetics, Epigenetic Drugs, and Delivery

Invited Speakers

Rojgopal Govindarajan, University of Georgia, U.S.A.
Vinod Labhasetwar, Cleveland Clinic Foundation, U.S.A.
Shujun Liu, University of Minnesota, U.S.A.

Epigenetic profiles are relevant to tumor growth rate, metastasis, and drug sensitivity. Epigenetic modulation has become a new research tide in cancer chemotherapy. Epigenetic control at multiple levels of DNA, histone, and chromatin offers open opportunity of new drug discovery as well as combinatory drug delivery. Due to their physicochemical properties, short half-lives, and potential systemic effects, focal delivery of epigenetic drugs becomes critical in epigenetic modulation and managing cancers with fewer side effects and longer life span. This mini-symposium introduces cancer epigenetics, epigenetic drug discovery, and delivery technology.


Wednesday, July 16 • 08:00 - 09:30

Individualized Medicine and Theranostics

Invited Speakers

Xiaoyuan Shawn Chen, NIH, U.S.A.
Yong-Min Huh, Yonsei University, Korea
Twan Lammers, Aachen University, Germany

Individualized medicine has been a hot topic for several years, dealing with the philosophy of having a companion diagnostic developed when commercializing a novel drug. The potential of combining both properties in one compound to develop personalized healthcare solutions is enormous, but there are also still multiple challenges before theranostics will get to the market. This mini-symposium will focus on recent innovations in these exciting areas. In particular, the potential influence of novel theranostic agents for personalized medication will be discussed.

© Copyright Controlled Release Society  | Contact Us - Report a Bad Link |
Admin Access